Business ❯ Pharmaceutical Industry

Research and Development

Clinical Trials Innovation Clinical Research Cost Reduction Investment Health Innovations Partnerships Collaboration Regulatory Compliance Collaborations Market Trends Market Strategy Funding for Health Contractual Relationships Drug Discovery AI Integration Biopharmaceuticals Clinical Development Innovative Drugs Innovative Methods Investment Strategies Malaria Treatments Market Approval Corporate Expansion Investment in Health Drug Competition AI in Medicine Strategic Decisions Product Development Sanofi Investment Trends Technology Transfer Healthcare Innovation Product Launch Intellectual Property

Claude AI Designed Lab‑Confirmed Protein Binders for 14 of 15 Disease Targets

Lab builds confirmed about 27% of Claude's de novo designs bound, suggesting early drug discovery is now limited by compute and wet‑lab throughput.

Bristol Myers Squibb Buys Second NVIDIA DGX SuperPOD Built on Vera Rubin

C-BRAIN Releases Open‑Source AI Toolbox to Speed Alzheimer’s Research

Boehringer’s Dual-Agonist Survodutide Cuts Body Weight by Up to 16.6% in Phase III Trial

EU Drug Panel Backs Sanofi’s Cenrifki for Non‑Relapsing SPMS

OpenAI Launches GPT-Rosalind, a Biology-Tuned AI for Drug Discovery

Novo’s Triple-Hormone Obesity Drug UBT251 Hits 19.7% Mean Weight Loss in China Phase 2

Sanofi’s Venglustat Notches Gaucher Type 3 Phase 3 Win, Misses Fabry Pain Endpoint

FDA Issues Draft Guidance Easing Primate Tests for Some Antibody Drugs

First New Antimalarial in Decades Tops 97% Cure in Phase III as Novartis Seeks Approval